【减肥神药 GLP-1受体激动剂与骨质流失⚠️⚠️⚠️】
2026年初的最新数据显示，虽然GLP-1受体激动剂（如索玛鲁肽和替泽帕肽）在体重管理方面具有革命性意义，但它们确实会带来“骨骼代价”，需要积极管理。

目前普遍认为，骨质流失主要是快速减肥和骨骼机械负荷减少的副作用，尽管一些研究表明，这些药物也可能对骨转换产生直接的、尽管较小的生物学影响。

2026年研究的主要发现

骨质疏松风险增加：一项在2026年3月美国骨科医师学会（AAOS）年会上发表的重要研究发现，与非使用者相比，GLP-1使用者在五年内患骨质疏松的风险高出30%。

骨密度下降：临床试验表明，接受司美格鲁肽治疗一年后，髋部骨密度（BMD）可下降约2.6%，腰椎骨密度可下降约2.1%。作为参考，这大约是绝经后女性典型骨丢失率的两倍。

“脱钩”效应：研究人员注意到一种生理性脱钩现象，即骨吸收（分解）增加，但骨形成（构建）并未相应增加以进行补偿。这种情况通常会因“肌肉-骨骼单元”而加剧——随着肌肉和脂肪的减少，骨骼失去了维持密度所需的机械刺激。

骨软化症相对风险更高：同一项美国骨科医师学会（AAOS）的研究表明，虽然骨软化症（骨骼软化）较为罕见，但在GLP-1组中，其相对风险是其他组的两倍以上。

GLP-1s & Bone Loss ⚠️⚠️⚠️

Recent data from early 2026 suggests that while GLP-1 receptor agonists (like semaglutide and tirzepatide) are revolutionary for weight management, they do present a real "skeletal cost" that requires proactive management.

The emerging consensus is that bone loss is largely a side effect of rapid weight loss and reduced mechanical loading on the skeleton, though some studies suggest the drugs may also have a direct, albeit minor, biological impact on bone turnover.

Key Findings from 2026 Research

Increased Risk of Osteoporosis: A major study presented at the March 2026 American Academy of Orthopaedic Surgeons (AAOS) annual meeting found that GLP-1 users had a 30% higher risk of developing osteoporosis over a five-year period compared to non-users.

Bone Density Decline: Clinical trials have shown that one year of semaglutide therapy can reduce hip bone mineral density (BMD) by approximately 2.6% and lumbar spine density by 2.1%. For context, this is roughly double the typical rate of bone loss seen in postmenopausal women.

The "Uncoupling" Effect: Researchers have noted a physiological uncoupling where bone resorption (breakdown) increases, but bone formation (building) does not rise to compensate. This is often exacerbated by the "muscle-bone unit"—as muscle mass is lost alongside fat, the bones lose the mechanical stimulus they need to stay dense.

Higher Relative Risk for Osteomalacia: The same AAOS study indicated that while rare, the relative risk for osteomalacia (bone softening) was more than double in the GLP-1 group.

Video: Dr. Karan Rajan http://t.cn/AXMcKssP